Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01

NCT02382913 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT02382913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2015
Completion date
June 30, 2015
Enrollment
315 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pertussis